

### 2.2 Publications listed in the PUBMED server and SIGAPS software without MERRI receipts

Center Jean Perrin authors appear in the list of investigators but not in the list of referenced authors. These publications do not generate MERRI revenues. They do, however, reflect the Centre's national and international reputation.

**1.** M R SMITH, M HUSSAIN, F SAAD, K FIZAZI, C N STERNBERG, E D CRAWFORD, E KOPYLTISOV, CR H PARK, B ALEKSEEV, Á MONTESA-PINO, D YE, F PARNIS, F CRUZ, T L J TAMMELA, H SUZUKI, T UTRIAINEN, C FU, M UEMURA, M J MENDEZ-VIDAL, B L MAUGHAN, H JOENSUU, S THIELE, R LI, I KUSS, B TOMBAL; ARASENS TRIAL INVESTIGATORS – **H MAHAMMEDI** Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer N Engl J Med 2022 Mar 24 ;386(12) :1132-1142 I.F : 176.079 SIGAPS : A+ Inv

**2.** M R SMITH, M HUSSAIN, F SAAD, K FIZAZI, C N STERNBERG, E D CRAWFORD, E KOPYLTISOV, CR H PARK, B ALEKSEEV, Á MONTESA-PINO, D YE, F PARNIS, F CRUZ, T L J TAMMELA, H SUZUKI, T UTRIAINEN, C FU, M UEMURA, M J MENDEZ-VIDAL, B L MAUGHAN, H JOENSUU, S THIELE, R LI, I KUSS, B TOMBAL; ARASENS TRIAL INVESTIGATORS – **H MAHAMMEDI** Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer N Engl J Med 2022 Mar 24 ;386(12) :1132-1142

I.F : 176.079 SIGAPS : A+ Inv

**3.** J-P FRAT, J-P QUENOT, J BADIE, R COUDROY, C GUITTON, S EHRMANN, A GACOUIN, H MERDJI, J AUCHABIE, C DAUBIN, A-F DUREAU, L THIBAUT, N SEDILLOT, J-P RIGAUD, A DEMOULE, A FATAH, N TERZI, M SIMONIN, W DANJOU, G CARTEAUX, C GUESDON, G PRADEL, M-C BESSE, J REIGNIER, F BELONCLE, B LA COMBE, G PRAT, M-A NAY, J DE KEIZER, S RAGOT, A W THILLE; SOHO-COVID STUDY GROUP AND THE REVA NETWORK – **A LAUTRETTE** Effect of High-Flow Nasal Cannula Oxygen vs Standard Oxygen Therapy on Mortality in Patients With Respiratory Failure Due to COVID-19 : The SOHO-COVID randomized Clinical Trial JAMA. 2022 Sep 27 ;328(12) :1212-1222

I.F : 157.335 SIGAPS : A+ inv

**4.** C E GEYER JR, J E GARBER, R D GELBER, G YOTHERS, M TABOADA, L ROSS, P RASTOGI, K CUI, A ARAHMANI, G AKTAN, A C ARMSTRONG, M ARNELOS, J BALMAÑA, J BERGH, J BLISS, S DELALOGUE, S M DOMCHEK, A EISEN, F ELSAFY, L E FEIN, A FIELDING, J M FORD, S FRIEDMAN, K A GELMON, L GIANNI, M GNANT, S J HOLLINGSWORTH, S-A IM, A JAGER, Ó P JOHANSSON, S R LAKHANI, W JANNI, B LINDERHOLM, T-W LIU, N LOMAN, L KORDE, S LOIBL, P C LUCAS, F MARME, E MARTINEZ DE DUEÑAS, R MCCONNELL, K-A PHILLIPS, M PICCART, G ROSSI, R SCHMUTZLER, E SENKUS, Z SHAO, P SHARMA, C F SINGER, T ŠPANIC, E STICKELER, M TOI, T A TRAINA G VIALE, G ZOPPOLI, Y H PARK, R YERUSHALMI, H YANG, D PANG, K H JUNG, A MAILLIEZ, Z FAN, I TENNEVET, J ZHANG, T NAGY, G S SONKE, Q SUN, M PARTON, M A COLLEONI, M SCHMIDT, A M BRUFISKY 1, W RAZAQ, B KAUFMAN, D CAMERON, C CAMPBELL, A N J TUTT; OLYMPIA CLINICAL TRIAL STEERING COMMITTEE AND INVESTIGATORS – **M-A MOURET-REYNIER** Overall survival in the OlympiA phase III trial of adjuvant olaparib in patients with germline pathogenic variants in BRCA1/2 and high-risk, early breast cancer Ann Oncol. 2022 Dec ;33(12) :1250-1268

I.F : 51.769 SIGAPS : A Inv

**5.** M COUR, K KLOUCHE, B SOUWEINE, J-P QUENOT, C SCHWEBEL, S PERINEL, C AMAZ, M BUISSON, M OVIZE, N MEWTON, LAURENT ARGAUD; RECO-SEPSIS TRIAL INVESTIGATORS – **A LAUTRETTE** Remote ischemic conditioning in septic shock : the RECO-Sepsis randomized clinical trial Intensive Care Med. 2022 Nov ;48(11) :1563-1572

I.F : 41.787 SIGAPS : A Inv

- 6.** IVERGOTE, A GONZALEZ-MARTIN, I RAY-COQUARD, P HARTEY, N COLOMBO, P PUJOL, D LORUSSO, M R MIRZA, B BRASIUNIENE, R MADRY, J D BRENTON, M G E M AUSEMS, R BÜTTNER, D LAMBRECHTS; EUROPEAN EXPERTS' CONSENSUS GROUP – **F PENAULT-LLORCA** European experts consensus : BRCA/ homologous recombination deficiency testing in first-line ovarian cancer *Ann Oncol.* 2022 Mar ;33(3) :276-287  
I.F : 51.769 SIGAPS : A Inv
- 7.** A SAADE, A BOURMAUD, D SCHNELL, M DARMON; R2D2 STUDY GROUP Performance of Doppler-Based Resistive Index and Semi-quantitative Renal Perfusion in Predicting Persistent Acute Kidney Injury According to Operator Experience : Post Hoc Analysis of a Prospective Multicenter Study *Crit Care Med.* 2022 Apr 1 ;50(4) :e634-e639  
I.F : 9.296 SIGAPS : B Inv
- 8.** E DE MONTMOLLIN, C DUPUIS, P JAQUET, B SARTON, C SAZIO, V SUSSET, M CONRAD, L ARGAUD, S DEMERET, J M TADIE, F BARBIER, M WOLFF, J-F TIMSIT, B VISSEAU, R SONNEVILLE; ENCEPHALITICA STUDY GROUP – **A LAUTRETTE** Herpes simplex virus encephalitis with initial negative polymerase chain reaction in the cerebrospinal fluid : prevalence, associated factors, and clinical impact *Crit Care Med.* 2022 Jul 1 ;50(7) :e643-e648  
I.F : 9.296 SIGAPS : B Inv
- 9.** P BURMAN, J TROUILLAS, M LOSA, A MCCORMACK, S PETERSENN, V POPOVIC, M THEODOROPOULOU, G RAVEROT, O M DEKKERS; ESE SURVEY COLLABORATORS – **M BATISSE-LIGNIER** Aggressive pituitary tumours and carcinomas, characteristics and management of 171 patients. *Eur J Endocrinol.* 2022 Sep 19 ;187(4) :593-605  
I.F : 6.558 SIGAPS : B Inv
- 10.** F BERGER, M MARCE, S DELALOGUE, A-C HARDY-BESSARD, T BACHELOT, I BIECHE, A PRADINES, T DE LA MOTTE ROUGE, J-L CANON, F ANDRE, L ARNOULD, F CLATOT, J LEMONNIER, S MARQUES, F-C BIDARD; PADA-1 INVESTIGATORS – **M-A MOURET-REYNIER** Randomised, open-label, multicentric phase III trial to evaluate the safety and efficacy of palbociclib in combination with endocrine therapy, guided by ESR1 mutation monitoring in oestrogen receptor-positive, HER2-negative metastatic breast cancer patients : study design of PADA-1 *BMJ Open.* 2022 Mar 3 ;12(3) :e055821  
I.F : 3.006 SIGAPS : C Inv